Resultados 3T26

Receita trimestral supera R$ 500 mi pela primeira vez, com melhora das margens e geração de caixa


Destaques do trimestre

- Crescimento de Receita impulsionado pelo Segmento Hospitalar (+11%).
- Margem Bruta e EBITDA aceleram em relação ao 1S26.
- Geração de caixa livre 3,4x maior, por melhora operacional, otimização de capital de giro e priorização de investimentos.


Desempenho Operacional 3T26 (vs. 3T25)

Receita Hospitalar	Margem Bruta	Margem EBITDA	Fluxo de Caixa Op.
R$ 431 mi	43,2%	25,3%	R$ 213 mi
+11%	+260 bps	+120 bps	+49%

Lançamentos ganham relevância na receita



mAbs podem triplicar o mercado endereçável



Geração de caixa e endividamento 3T26 (vs. 2T26)

Posição de Caixa	Dívida Bruta	Caixa Líquido	Alavancagem
R$ 1,0 bi	R$ 910 mi	R$ 98 mi	-0,2x
+ BRL 124 mi	+ BRL 89 mi	+ BRL 34 mi	Dívida Líquida/EBITDA

Resultados 9M26

Blau FARMACÊUTICA

Desempenho consolida os avanços nos resultados dos últimos 3 anos


Destaques 9M26

- Crescimento de Receita impulsionado pelo Segmento Hospitalar (+10%).
- Margens mantêm a tendência positiva dos últimos 3 anos, com melhora da conversão em caixa.
- Geração de caixa livre de R$ 158 mi, revertendo consumo de R$ 58 mi no 9M25.


Desempenho Operacional 9M26 (vs. 9M25)


Receita líquida	Margem Bruta	Margem EBITDA	Fluxo de Caixa Op.
R$ 1,4 bi	**42,8%**	**25,1%**	**R$ 425 mi**
+9%	+250 bps	+70 bps	+84%

Desempenho Últimos 3 anos:




*Anualizada





Receita por Região


Internacional
R$ 137 mi (+24%)



Brasil
R$ 1.291 mi (+7%)

Receita por Segmento

Varejo, Estética e Plasma
R$ 188 mi (estável)



Hospitalar
R$ 1.240 mi (+10%)

3Q26 Results

Quarterly revenue exceeds R$ 500 million for the first time, with improved margins and cash generation


Quarter Highlights

- Revenue Growth driven by the Hospital Segment (+11%).
- Gross Margin and EBITDA accelerate compared to 1H26.
- Free cash generation 3.4x higher, due to operational improvement, working capital optimization and prioritization of investments.


Operational Performance 3Q26 (vs. 3Q25)

Hospital Segment	Gross Margin	EBITDA Margin	Operational Cash Flow
R$ 431 mi	43.2%	25.3%	R$ 213 mi
+11%	+260 bps	+120 bps	+49%

Launches gain relevance in revenue



mAbs can triple the addressable market



Cash generation and debt in 3Q26 (vs. 2Q26)

Cash Position	Gross Debt	Net Cash	Leverage
R$ 1,0 bi	R$ 910 mi	R$ 98 mi	-0.2x
+ BRL 124 mi	+ BRL 89 mi	+ BRL 34 mi	Net Debt/EBITDA

9M26 Results

Performance consolidates the advances in the results of the last 3 years


9M26 Highlights


- Revenue Growth driven by the Hospital Segment (+10%).
- Margins maintain the positive trend of the last 3 years, with improved conversion into cash.
- Free cash generation of R$158 million, reversing consumption of R$58 million in 9M25.


Operating Performance 9M26 (vs. 9M25)

Net revenue	Gross Margin	EBITDA Margin	Operational Cash Flow
R$ 1.4 bi	42.8%	25.1%	R$ 425 mi
+9%	+250 bps	+70 bps	+84%

Performance Last 3 years:








Revenue by Region


International
R$ 137 mi (+24%)



Brazil
R$ 1.291 mi (+7%)

Revenue by Segment

Retail, Aesthetics and Plasma
R$ 188 mi (stable)



Hospital
R$ 1.240 mi (+10%)